Sugi Predict

Sugi Predict / Compounds / SCHEMBL14745101

SCHEMBL14745101

SCHEMBL14745101

Cc1ccc(S(=O)(=O)OCCOCCOCCOCCOCCNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 8/20 0.52
▸ CA2 P00918 8/20 0.52
▸ CA12 O43570 5/20 0.52
▸ CA9 Q16790 5/20 0.52
▸ ALDH1A1 P00352 1/20 0.45
▸ ADRB2 P07550 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ BCHE P06276 2/20 0.41
▸ CNR2 P34972 2/20 0.41
▸ IDO1 P14902 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6757589 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL21071071 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL26102679 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL3289002 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL21531171 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL31235782 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL8073830 1.00 CA1 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL17162059 0.94 CA1 (0.49) CA1CA2CA12CA9ALDH1A1
SCHEMBL22326317 0.93 CA1 (0.51) CA1CA2CA12CA9ALDH1A1
SCHEMBL791306 0.92 CA2 (0.56) CA1CA2CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113480453-B Synthesis method of NH2-PEG5-NHBoc 苏州昊帆生物股份有限公司 2023-04-04 — — CN claimed
CN-113480453-A Synthesis method of NH2-PEG5-NHBoc 苏州昊帆生物股份有限公司 2021-10-08 — — CN claimed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
WO-2025104141-A1 NOVEL REVERSIBLE FLUORESCENT PROBES FOR CB2 F. HOFFMANN-LA ROCHE AG (CH) 2025-05-22 — — WO disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250145611-A1 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. 2025-05-08 — — US disclosed
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
WO-2013033268-A2 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2013-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 CA1 3444/4885CA2 3216/4885CA12 3591/4885
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CA1 4622/4885CA2 4617/4885CA12 4583/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA1 4622/4885CA2 4617/4885CA12 4583/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA1 4622/4885CA2 4617/4885CA12 4583/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CA1 4622/4885CA2 4617/4885CA12 4583/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA1 4622/4885CA2 4617/4885CA12 4583/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 CA1 3789/4885CA2 2041/4885CA12 3947/4885
US-20250145611-A1 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 CA1 4531/4885CA2 3954/4885CA12 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.